- Home
- BMY vs VRTX Comparison
BMY vs VRTX Comparison
Compare BMY & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMY
- VRTX
- Stock Information
- Founded
- BMY 1887
- VRTX 1989
- Country
- BMY United States
- VRTX United States
- Employees
- BMY N/A
- VRTX N/A
- Industry
- BMY Biotechnology: Pharmaceutical Preparations
- VRTX EDP Services
- Sector
- BMY Health Care
- VRTX Technology
- Exchange
- BMY Nasdaq
- VRTX Nasdaq
- Market Cap
- BMY 115.3B
- VRTX 104.8B
- IPO Year
- BMY N/A
- VRTX 1991
- Fundamental
- Price
- BMY $55.84
- VRTX $484.24
- Analyst Decision
- BMY Hold
- VRTX Buy
- Analyst Count
- BMY 14
- VRTX 25
- Target Price
- BMY $58.00
- VRTX $505.61
- AVG Volume (30 Days)
- BMY 11.5M
- VRTX 1.5M
- Earning Date
- BMY 02-06-2025
- VRTX 02-10-2025
- Dividend Yield
- BMY 4.44%
- VRTX N/A
- EPS Growth
- BMY N/A
- VRTX N/A
- EPS
- BMY N/A
- VRTX N/A
- Revenue
- BMY $48,300,000,000.00
- VRTX $11,020,100,000.00
- Revenue This Year
- BMY N/A
- VRTX $9.62
- Revenue Next Year
- BMY N/A
- VRTX $9.25
- P/E Ratio
- BMY N/A
- VRTX N/A
- Revenue Growth
- BMY 7.32
- VRTX 11.66
- 52 Week Low
- BMY $39.35
- VRTX $377.85
- 52 Week High
- BMY $61.10
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- BMY 45.21
- VRTX 65.58
- Support Level
- BMY $53.54
- VRTX $451.99
- Resistance Level
- BMY $56.54
- VRTX $469.55
- Average True Range (ATR)
- BMY 1.41
- VRTX 11.70
- MACD
- BMY -0.26
- VRTX 0.97
- Stochastic Oscillator
- BMY 33.72
- VRTX 83.48
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.